{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for amphotericin root_codes_comments in Code Comments (approximate match)
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2018)
Source URL:
First approved in 2018
Source:
21 CFR 352
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
First approved in 2015
Source:
NADA141438
Source URL:
Class:
MIXTURE
Targets:
Conditions:
Avilamycin is an orthosomycin antibiotic complex produced by the fermentation of Streptomyces viridochromogenes. Avilamycin is intended for use as a veterinary medicine in chickens, turkeys, pigs and rabbits to control bacterial enteric infections. It exhibits good antimicrobial activity against important veterinary Gram-positive pathogens (e.g., Clostridium perfringens) and has no related molecules in its class in human use. Therefore, avilamycin has been developed for treating necrotic enteritis in poultry, and enteric disease in pig and rabbits. Avilamycin inhibits bacterial protein synthesis through a novel mechanism of action by binding to the 50S ribosomal subunit and preventing the association of IF2, which inhibits the formation of the mature 70S initiation complex, and the correct positioning of tRNA in the aminoacyl site. No adverse drug-related changes were observed.
Status:
Possibly Marketed Outside US
Source:
21 CFR 347
(2014)
Source URL:
First approved in 2014
Source:
21 CFR 347
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NCT04160767: Phase 4 Interventional Unknown status Celiac Disease
(2019)
Source URL:
First approved in 2010
Source:
21 CFR 352
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333E
(2011)
Source URL:
First approved in 2010
Source:
21 CFR 352
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2010)
Source URL:
First approved in 2010
Source:
21 CFR 352
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
First approved in 2009
Source:
Bambermycin Concentrate by Biovet Joint Stock Company
Source URL:
Class:
MIXTURE
Targets:
Conditions:
Bambermycins (flavomycin) is a complex of antibiotics obtained from Streptomyces bambergiensis and Streptomyces ghanaensis used as a food additive for poultry and swine. Inhibitor of the in vitro transglycosylase activities of PBPs. Bambermycins complex consists mainly of moenomycins A and C. Moenomycin A is the prototype for compounds that bind to bacterial peptidoglycan glycosyltransferases (PGTs) and inhibit cell wall biosynthesis
Status:
Possibly Marketed Outside US
First approved in 2007
Source:
Virginiamycin by Phibro Saúde Animal Internacional Ltda.
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NADA141349
(2013)
Source URL:
First approved in 2005
Source:
NADA141244
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NDA021361
(2004)
Source URL:
First approved in 2004
Source:
NDA021361
Source URL:
Class:
MIXTURE